| NEOGENOMICS INC. |
| USA |
| Gesundheit |
| US64049M2098 / 120159 |
| NG9 (Frankfurt) / NEO (NASDAQ) |
| FRA:NG9, ETR:NG9, NG9:GR, NASDAQ:NEO |
| - |
| https://www.neogenomics.c.. |
|
NeoGenomics Inc. is a leading cancer diagnostics company specializing in oncology genetics testing and information services. It offers one of the most comprehensive menus of oncology-focused tests worldwide, including next-generation sequencing (NGS)..
>Volltext.. |
| 956.75 Mio. EUR |
| 1169.61 Mio. EUR |
| 621.02 Mio. EUR |
| -1.38 Mio. EUR |
| -92.23 Mio. EUR |
| -0.72 EUR |
| 349.61 Mio. EUR |
| 136.29 Mio. EUR |
| 4.47 Mio. EUR |
| 1.81 |
| -2.95% |
| -20.94% |
| - |
| - |
| - |
| - |
| NEOGENOMICS |
| 29.04.26 |